AI drug leadership Syntekabio is a AI-driven drug discovery and development company with a proprietary AI supercomputing infrastructure, strong emphasis on AI and NGS, and active collaborations with academic, industrial, and government partners. Sales opportunity: position AI platform services and collaboration models to pharma and biotech firms seeking faster hit discovery and target validation.

Global presence Headquartered in South Korea with a U.S. hub in New York City and ongoing US operations leadership. Sales opportunity: offer US market access, regulatory intelligence, and co-development programs through the New York hub to North American biotech and pharma companies seeking cross-border partnerships.

Strategic partnerships Recent collaborations with Enamine for AI-based synthetic drug development and a MetaVia partnership to explore additional indications indicate a collaborative growth model. Sales opportunity: propose joint development agreements, data-sharing, and integrated supply chain capabilities to accelerate compound generation and diversification.

Asset program expansion Launch of AI-driven Asset Programs in October 2025 aims to identify antibody and small-molecule candidates using proprietary AI infrastructure. Sales opportunity: market these asset discovery programs to biotech firms and pharma companies seeking preclinical candidates and faster time-to-IND paths.

Financial scale and growth Revenue in the tens of millions with substantial funding and a broad technology stack, indicating credible financial backing and capacity to scale collaborations. Sales opportunity: pursue larger multi-year SaaS or co-development deals, offering enterprise-grade solutions and dedicated support to mid-size to large partners seeking reliable AI-driven discovery pipelines.